Authors
Loading...
Network pharmacology reveals that HL-RG lowers targets in renal cell carcinoma, indicating its potential to improve treatment outcomes.
Duan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: